In his new role Ghomi will lead Optibrium’s Research Team in developing and implementing breakthrough methods, such as quantum mechanical and machine learning approaches, all intended to improve the productivity and efficiency of the drug discovery process. He will also work alongside the Software Development and Business Development teams, ensuring the translation of the company’s in-house R&D into valuable drug discovery tools and services. Previously, Ghomi worked at Illumina as bioinformatics manager, during which time he focused on computational protein engineering and small molecule design. He also holds various degrees, including a PhD in the Philosophy of Science from the University of Cambridge and a PhD in Computational Drug Design from Purdue University.

Commenting on his appointment, Ghomi stated: “I am delighted to be joining Optibrium at such a dynamic and exciting stage of growth. Its world-class team sits at the forefront of machine learning and quantum mechanical modelling, and I look forward to translating the Company’s breakthrough R&D into impactful solutions for our customers’ drug discovery programmes.”

Dr Matthew Segall, chief executive officer at Optibrium, added: “We are pleased to welcome Hamed to the team. His impressive depth of industry and academic experience, centred around computational chemistry and bioinformatics, will drive cutting-edge advances in Optibrium’s R&D, helping us to deliver the latest innovations in drug discovery to our users worldwide.”